MESENCHYMAL STEM CELL THERAPY FOR INFARCT

间充质干细胞治疗梗塞

• 批准号: 7960467
• 负责人: Chuanxi Cai
• 金额: $ 19.36万
• 依托单位: UNIVERSITY OF LOUISVILLE
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-07-01 至 2010-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7960467
• 关键词: Cardiac; Cardiomyopathies; Cardiovascular system; Computer Retrieval of Information on Scientific Projects Database; Coronary Arteriosclerosis; Diabetes Mellitus; Funding; Grant; Heart failure; Infarction; Institution; Mediating; Mesenchymal Stem Cells; Myocardial Infarction; Myocardial Ischemia; Nature; Obesity; Research; Research Personnel; Resources; Source; Therapeutic; United States National Institutes of Health; diabetes mellitus therapy; diabetic; diabetic patient; repaired; stem; stem cell therapy

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Nearly two-thirds of diabetics suffer from overt cardiovascular conditions, including coronary artery disease, myocardial infarction (MI), and cardiomyopathy. Despite the known systemic nature of diabetes, therapy for MI and ischemic cardiomyopathy are often not specifically tailored for diabetics, and the feasibility and efficacy of stem cell therapy for infarct repair in diabetic patients remains unclear. Although mesenchymal stem cells (MSCs) have been shown to induce infarct repair, the results have been variable and mechanisms remain controversial. The variability in MSC-mediated cardiac repair might have stemmed from the fundamentally heterogeneous nature of unfractionated 'MSCs'. We hypothesize that the use of a homogenous antigenically-defined MSC subpopulation with greater endothelial and cardiomyogenic differentiation potential and greater ability to secrete cardioprotective factors will result in superior cardiac repair in diabetics. These studies will identify the best MSC to use for infarct repair specifically in diabetics, and the results would have enormous therapeutic implications for diabetic patients with ischemic heart disease and post-MI heart failure.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 近三分之二的糖尿病患者患有明显的心血管疾病，包括冠状动脉疾病，心肌梗塞（MI）和心肌病。尽管糖尿病具有已知的全身性质，但MI和缺血性心肌病的治疗通常不是专门针对糖尿病患者量身定制的，糖尿病患者中干细胞治疗对梗塞修复的可行性和功效尚不清楚。尽管表现出间充质干细胞（MSC）诱导梗塞修复，但结果是可变的，机制仍然存在争议。 MSC介导的心脏修复的可变性可能源于未分流的“ MSC”的根本异质性质。我们假设使用具有更大的内皮和心肌分化潜力和分泌心脏保护因子的能力更大的均质抗原定义的MSC亚群，将导致糖尿病患者的心脏修复。这些研究将确定专门用于糖尿病患者的梗死修复的最佳MSC，结果将对患有缺血性心脏病和MI后心力衰竭的糖尿病患者具有巨大的治疗意义。